Here are the Form 4 insider transactions from Innoviva, Inc. (INVA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow INVA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INVA filings page.
Innoviva, Inc. (INVA) reported an insider equity-related transaction by Chief Accounting Officer Marianne Zhen. On 2026-08-20, 1,127 shares of common stock were disposed of at $21.00 per share through shares withheld by the company to satisfy income tax withholding obligations tied to quarterly vesting of previously granted employee equity grants. After this tax-withholding transaction, Zhen directly held 56,389 shares of Innoviva common stock.
Innoviva, Inc. (INVA) reported an insider transaction by Chief Financial Officer Stephen Basso. On August 20, 2026, 558 shares of common stock were disposed of at $21.00 per share to satisfy income tax withholding obligations related to the quarterly vesting of previously granted employee equity awards. Following this withholding, Basso beneficially owns 88,013 shares of Innoviva common stock held directly.
Innoviva, Inc. (INVA) reported an insider tax-related share withholding by Chief Executive Officer and director Pavel Raifeld. On 2026-08-20, 1,130 shares of common stock were disposed of at $21.00 per share to satisfy income tax withholding obligations tied to the quarterly vesting of previously granted equity awards. Following this withholding transaction, Raifeld directly owned 284,799 shares of Innoviva common stock.
Innoviva, Inc. Chief Financial Officer Stephen Basso reported routine equity compensation activity. On May 15, 2026, he acquired 1,123 shares of common stock through the company’s Employee Stock Purchase Plan. On May 20, 2026, 559 shares were withheld to cover income taxes on vesting of earlier equity awards, leaving him with 88,571 shares held directly. The withholding is not an open-market sale and reflects tax obligations tied to prior grants.
Innoviva, Inc. Chief Executive Officer Pavel Raifeld reported routine equity compensation activity. On May 15, he acquired 1,123 shares of common stock at no cost through the Innoviva Employee Stock Purchase Plan. On May 20, 1,130 shares were withheld by Innoviva to cover income taxes on quarterly vesting of prior equity grants, leaving him holding 285,929 shares directly. These transactions reflect compensation and tax withholding, not open-market buying or selling.
Innoviva, Inc. reported a routine insider transaction by Chief Accounting Officer Marianne Zhen. On May 20, 2026, 1,127 shares of common stock were withheld by the company at $22.24 per share to cover income tax obligations tied to the quarterly vesting of prior equity grants.
These shares were not sold on the open market but used to satisfy tax withholding. After this tax-withholding disposition, Zhen directly holds 57,516 shares of Innoviva common stock.
Innoviva, Inc. director Linden Josephine reported equity compensation awards tied to their appointment to the Board on May 18, 2026. They received 9,461 shares of common stock and a separate 5,733-share restricted stock unit grant, all at no cash cost. In addition, they were granted non-statutory stock options for 9,166 shares of common stock at an exercise price of $21.80 per share, expiring in 2036. The RSUs vest over two years, while the options and additional RSUs vest at the earlier of the next annual stockholder meeting or one year after the grant date, subject to continued service and certain acceleration events.
Innoviva, Inc. director Mark DiPaolo received new equity awards consisting of common stock and stock options. He was granted 9,786 shares of common stock as restricted stock units at no purchase price, increasing his direct holdings to 140,492 shares. He also received a non-statutory stock option for 10,000 shares of common stock at an exercise price of $22.99 per share, expiring in 2036.
According to the award terms, 100% of the RSUs and options will vest at the earlier of the next annual stockholder meeting or the one-year anniversary of the grant, subject to his continued service as an Outside Director. Vesting accelerates upon death, disability, or a qualifying change in control under the company’s 2026 Equity Incentive Plan.
Innoviva, Inc. reported that Chief Executive Officer Pavel Raifeld was conditionally granted equity awards as part of his compensation. He received 126,646 time-vested restricted stock units representing Common Stock and 312,500 non-statutory stock options with a $22.99 exercise price, subject to stockholder approval of the 2026 Equity Incentive Plan at the 2026 annual meeting on May 4, 2026. Twenty-five percent of each award vests on February 20, 2027, with the remaining portions vesting in twelve substantially equal quarterly installments, assuming continued service and certain change-in-control protections. Following the grant, he directly holds 285,936 shares of Common Stock and 312,500 options.
Innoviva, Inc. reported that Chief Accounting Officer Marianne Zhen acquired equity awards as compensation. She was conditionally granted 12,766 time-vested restricted stock units and 31,500 non-statutory stock options with an exercise price of $22.99 per share, each for Innoviva common stock.
The awards are subject to stockholder approval of Innoviva's 2026 Equity Incentive Plan at the 2026 annual meeting on May 4, 2026. Twenty-five percent of both the RSUs and options vest on February 20, 2027, with the remainder vesting in twelve equal quarterly installments, subject to continued service and certain change-in-control and involuntary termination provisions. Following the grant, Zhen directly holds 58,643 common shares and 31,500 options.
Innoviva, Inc. director Sarah J. Schlesinger received new equity compensation awards. She was granted 9,786 shares of common stock in the form of restricted stock units and a non-statutory stock option for 10,000 shares at an exercise price of $22.99 per share.
These grants were made following Innoviva’s 2026 annual meeting of stockholders and are compensation awards, not open-market purchases. All of the RSUs and options vest 100% at the earlier of the next annual stockholder meeting or the one-year anniversary of the grant, contingent on her continued service as an Outside Director, with accelerated vesting upon death, disability, or a qualifying change in control under the 2026 Equity Incentive Plan.
After these awards, she directly holds 140,492 shares of common stock and 10,000 options.
Innoviva, Inc. reported that its Chief Financial Officer, Stephen Basso, received equity-based compensation awards. He was granted 37,994 time-vested restricted stock units of common stock and a non-statutory stock option for 93,750 shares at an exercise price of $22.99 per share.
These RSUs and options were conditionally granted under Innoviva's 2026 Equity Incentive Plan, subject to stockholder approval at the 2026 annual meeting on May 4, 2026. Twenty-five percent of each award vests on February 20, 2027, with the remaining portions vesting in twelve equal quarterly installments, assuming continued service.
The vesting schedule includes potential accelerated vesting in certain change in control and involuntary termination scenarios as defined in the 2026 Equity Incentive Plan. Following the RSU grant, Basso directly holds 88,007 shares of Innoviva common stock.
Innoviva, Inc. director Derek A. Small received equity awards tied to his board service. He acquired 9,786 shares of common stock through restricted stock units at no cost and now holds 45,035 shares directly. He was also granted non-statutory stock options for 10,000 shares of common stock at an exercise price of $22.99 per share, expiring in 2036. All RSUs and options vest 100% at the earlier of the next annual stockholder meeting or the one-year anniversary of grant, with accelerated vesting upon death, disability, or certain change in control events.
Haimovitz Jules reported acquisition or exercise transactions in this Form 4 filing.
Innoviva, Inc. director Jules Haimovitz received equity compensation in the form of restricted stock units and stock options. He was granted 9,786 shares of Common Stock as RSUs and 10,000 non-statutory stock options, each option exercisable at $22.9900 per share.
All of the RSUs and options vest 100% at the earlier of the next annual stockholder meeting or the one-year anniversary of the May 4, 2026 grant, subject to his continuous service as an Outside Director. Vesting accelerates upon death, disability, or a qualifying change in control under Innoviva’s 2026 Equity Incentive Plan. Following the stock award, Haimovitz directly holds 152,692 shares of Common Stock and 10,000 options.
Innoviva, Inc. Chief Financial Officer Stephen Basso reported a tax-related share disposition. On February 20, 2026, 1,244 shares of common stock were withheld by the company at $23.39 per share to satisfy income tax obligations on vesting equity awards. After this withholding, Basso directly owns 50,013 shares of Innoviva common stock.
Innoviva, Inc. Chief Executive Officer Pavel Raifeld reported a tax-related share disposition. On the vesting of previously granted equity, 2,986 shares of common stock were withheld by the company at $23.39 per share to cover income tax obligations. After this withholding transaction, Raifeld directly owned 159,290 shares of Innoviva common stock.
Innoviva, Inc. Chief Accounting Officer Marianne Zhen reported a routine tax-related share disposition. On February 20, 2026, 2,460 shares of common stock were withheld at $23.39 per share to cover income tax obligations tied to vesting of prior equity grants, leaving her with 45,877 directly owned shares.
Innoviva, Inc. (INVA) reported insider equity activity for its Chief Financial Officer, Stephen Basso, on a Form 4. On November 15, 2025, he acquired 604 shares of common stock at $0 under the Innoviva Employee Stock Purchase Plan. On November 20, 2025, 237 shares of common stock were withheld by Innoviva at $21.16 per share to cover income tax obligations tied to the quarterly vesting of previously granted equity awards. After these transactions, he directly owned 51,257 shares of Innoviva common stock.
Innoviva, Inc. (INVA) reported a routine insider transaction by its Chief Accounting Officer, who filed a Form 4 for a tax-related share withholding. On 11/20/2025, 992 shares of common stock were withheld by Innoviva at a price of $21.16 per share to cover income tax obligations tied to the quarterly vesting of previously granted employee equity awards. After this withholding, the reporting person beneficially owned 48,337 shares of Innoviva common stock directly.